04:54 AM EDT, 05/31/2024 (MT Newswires) -- Prelude Therapeutics ( PRLD ) filed Thursday a registration statement covering the potential sale of up to $400 million of securities from time to time.

The securities include common stock, preferred stock, debt securities, warrants, subscription rights and units.

Unless otherwise provided in a prospectus supplement, the company said it expects to use the proceeds for general corporate purposes, including funding research, clinical and process development and manufacturing of tis product candidates, as well as for reducing debt.

Price: 3.7900, Change: -0.08, Percent Change: -2.07